Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline

Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT...

Full description

Saved in:
Bibliographic Details
Main Authors: David J. Blacker, David Prentice, Anthony Alvaro, Timothy R. Bates, Michael Bynevelt, Andrew Kelly, Lay Kun Kho, Edith Kohler, Graeme J. Hankey, Andrew Thompson, Taryn Major
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Stroke Research and Treatment
Online Access:http://dx.doi.org/10.1155/2013/362961
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849307131412480000
author David J. Blacker
David Prentice
Anthony Alvaro
Timothy R. Bates
Michael Bynevelt
Andrew Kelly
Lay Kun Kho
Edith Kohler
Graeme J. Hankey
Andrew Thompson
Taryn Major
author_facet David J. Blacker
David Prentice
Anthony Alvaro
Timothy R. Bates
Michael Bynevelt
Andrew Kelly
Lay Kun Kho
Edith Kohler
Graeme J. Hankey
Andrew Thompson
Taryn Major
author_sort David J. Blacker
collection DOAJ
description Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) aims to determine the safety and efficacy of adding minocycline to tPA in acute ischaemic stroke. The WAIMATSS is a multicentre, prospective, and randomised pilot study of intravenous minocycline, 200 mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tPA. The primary endpoint is HT diagnosed by brain CT and MRI. Secondary endpoints include clinical outcome measures. Some illustrative cases from the early recruitment phase of this study will be presented, and future perspectives will be discussed.
format Article
id doaj-art-1d0eb60e3c9f4d0295247bbca4fec341
institution Kabale University
issn 2090-8105
2042-0056
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Stroke Research and Treatment
spelling doaj-art-1d0eb60e3c9f4d0295247bbca4fec3412025-08-20T03:54:51ZengWileyStroke Research and Treatment2090-81052042-00562013-01-01201310.1155/2013/362961362961Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising MinocyclineDavid J. Blacker0David Prentice1Anthony Alvaro2Timothy R. Bates3Michael Bynevelt4Andrew Kelly5Lay Kun Kho6Edith Kohler7Graeme J. Hankey8Andrew Thompson9Taryn Major10Department of Neurology and Clinical Neurophysiology, Sir Charles Gairdner Hospital, Nedlands, Western Australia and School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, AustraliaDepartment of General Medicine, Royal Perth Hospital, Perth, WA 6000, AustraliaDepartment of Neurology, Fremantle Hospital, Fremantle, WA 6160, AustraliaStroke Unit, Swan District Hospital, Middle Swan WA 6056, School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, AustraliaDepartment of Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, AustraliaDepartment of Neurology, Fremantle Hospital, Fremantle, WA 6160, AustraliaStroke Unit, Swan District Hospital, Middle Swan, WA 6056, AustraliaDepartment of General Medicine, Royal Perth Hospital, Perth, WA 6000, AustraliaDepartment of Neurology, Royal Perth Hospital, Perth WA 6000, School of Medicine and Pharmacology, The University of Western Australia, Nedlands, WA 6009, AustraliaDepartment of Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, AustraliaData Analysis Australia, Nedlands, WA 6009, AustraliaHaemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) aims to determine the safety and efficacy of adding minocycline to tPA in acute ischaemic stroke. The WAIMATSS is a multicentre, prospective, and randomised pilot study of intravenous minocycline, 200 mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tPA. The primary endpoint is HT diagnosed by brain CT and MRI. Secondary endpoints include clinical outcome measures. Some illustrative cases from the early recruitment phase of this study will be presented, and future perspectives will be discussed.http://dx.doi.org/10.1155/2013/362961
spellingShingle David J. Blacker
David Prentice
Anthony Alvaro
Timothy R. Bates
Michael Bynevelt
Andrew Kelly
Lay Kun Kho
Edith Kohler
Graeme J. Hankey
Andrew Thompson
Taryn Major
Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
Stroke Research and Treatment
title Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
title_full Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
title_fullStr Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
title_full_unstemmed Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
title_short Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline
title_sort reducing haemorrhagic transformation after thrombolysis for stroke a strategy utilising minocycline
url http://dx.doi.org/10.1155/2013/362961
work_keys_str_mv AT davidjblacker reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT davidprentice reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT anthonyalvaro reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT timothyrbates reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT michaelbynevelt reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT andrewkelly reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT laykunkho reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT edithkohler reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT graemejhankey reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT andrewthompson reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline
AT tarynmajor reducinghaemorrhagictransformationafterthrombolysisforstrokeastrategyutilisingminocycline